I would like to propose ReNeuron (RENE), which awaits FDA approval for start of a phase I trial on a stem cell procedure for victims of strokes. There is an 85% certainty of RENE getting IND1 Approval on the 30 day fast-track basis that should be settled by 5th January. I am looking for 20% on 40p = 48p by 12th January. Closed yesterday at 41.5p, up 1.5p, offered at 42p.
There may be a minor retracement before additional buying on the back of Broker's note with 106p target for stroke procedure alone; and 'human interest' angle as newspapers report progress (a 2007 tip by the Telegraph); Mesoblast [ASX:MSB] which got similar stem cell procedure approval up from A$1.77 on approval 18/12 to A$2.01 this morning [+13.6%]
